1. Home
  2. JJSF vs DNLI Comparison

JJSF vs DNLI Comparison

Compare JJSF & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JJSF
  • DNLI
  • Stock Information
  • Founded
  • JJSF 1971
  • DNLI 2013
  • Country
  • JJSF United States
  • DNLI United States
  • Employees
  • JJSF N/A
  • DNLI N/A
  • Industry
  • JJSF Specialty Foods
  • DNLI Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • JJSF Consumer Staples
  • DNLI Health Care
  • Exchange
  • JJSF Nasdaq
  • DNLI Nasdaq
  • Market Cap
  • JJSF N/A
  • DNLI 2.1B
  • IPO Year
  • JJSF N/A
  • DNLI 2017
  • Fundamental
  • Price
  • JJSF $116.61
  • DNLI $14.57
  • Analyst Decision
  • JJSF Buy
  • DNLI Strong Buy
  • Analyst Count
  • JJSF 2
  • DNLI 15
  • Target Price
  • JJSF $142.50
  • DNLI $33.85
  • AVG Volume (30 Days)
  • JJSF 188.7K
  • DNLI 1.5M
  • Earning Date
  • JJSF 08-04-2025
  • DNLI 07-31-2025
  • Dividend Yield
  • JJSF 2.68%
  • DNLI N/A
  • EPS Growth
  • JJSF N/A
  • DNLI N/A
  • EPS
  • JJSF 3.89
  • DNLI N/A
  • Revenue
  • JJSF $1,585,410,000.00
  • DNLI N/A
  • Revenue This Year
  • JJSF $3.64
  • DNLI N/A
  • Revenue Next Year
  • JJSF $3.68
  • DNLI $335.74
  • P/E Ratio
  • JJSF $29.92
  • DNLI N/A
  • Revenue Growth
  • JJSF 0.49
  • DNLI N/A
  • 52 Week Low
  • JJSF $109.71
  • DNLI $10.57
  • 52 Week High
  • JJSF $180.80
  • DNLI $33.33
  • Technical
  • Relative Strength Index (RSI)
  • JJSF 50.81
  • DNLI 51.34
  • Support Level
  • JJSF $115.10
  • DNLI $14.12
  • Resistance Level
  • JJSF $119.24
  • DNLI $15.38
  • Average True Range (ATR)
  • JJSF 3.23
  • DNLI 0.66
  • MACD
  • JJSF 0.43
  • DNLI 0.07
  • Stochastic Oscillator
  • JJSF 58.10
  • DNLI 59.03

About DNLI Denali Therapeutics Inc.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Share on Social Networks: